We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
29 Aug 2020 - 02 Sep 2020
Virtual Venue

Novel Thrombectomy Catheter Targets Deep Vein Thrombosis

By HospiMedica International staff writers
Posted on 16 Dec 2015
Print article
The AngioJet ZelanteDVT thrombectomy catheter
The AngioJet ZelanteDVT thrombectomy catheter (Photo courtesy of BOSTON SCIENTIFIC, INC)
A new thrombectomy catheter has been specifically designed to treat deep vein thrombosis (DVT) in large-diameter upper and lower peripheral veins.

The AngioJet ZelanteDVT thrombectomy catheter is indicated for the disruption and removal of large venous clot burdens from iliofemoral and lower extremity veins greater than or equal to 6 mm in diameter, and upper extremity peripheral veins greater than or equal to 6 mm in diameter. The 8 F (2.7 mm) catheter is the largest and strongest thrombectomy catheter in the AngioJet portfolio, with four times the thrombus removal power of previous generation catheters, and is used in conjunction with the AngioJet Ultra Console.

The 105 centimeters long thrombectomy catheter, which utilizes an over-the-wire guidewire and sheath for delivery, is torqueable and directional, enabling rapid thrombus removal, and is also PowerPulse enabled for the infusion of physician-specified fluids, including thrombolytic agents into the peripheral vascular system. The AngioJet ZelanteDVT thrombectomy catheter is a product of Boston Scientific (Natick, MA, USA), and has been approved by the US Food and Drug Administration (FDA).

“The new features of the ZelanteDVT catheter represent our focus on improving procedural efficiencies and reducing the economic burden associated with this challenging condition,” said Jeff Mirviss, peripheral interventions president at Boston Scientific. “With this addition to our AngioJet portfolio, we are further evolving the current suite of life-changing therapeutic options available to physicians and their patients with deep vein thrombosis.”

DVT commonly affects peripheral veins (such as the femoral vein, the popliteal vein, or the iliofemoral vein), and can occur without any symptoms. In many cases the affected extremity will be painful, swollen, red, and warm, and the superficial veins may be engorged. The most serious complication of a DVT is that the clot could dislodge and cause a pulmonary embolism (PE). DVT is a medical emergency and untreated lower extremity DVT has a 3% PE-related mortality rate.

Related Links:

Boston Scientific

Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get complete access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every 2 weeks containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
Click here to Register



view channel

Siemens to Acquire Varian Medical to Create Comprehensive Cancer Portfolio

Siemens Healthineers (Erlangen, Germany) has entered into an agreement to acquire Varian Medical Systems, Inc. (Palo Alto, CA, USA) that will lead to the creation of a global leader in healthcare with... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.